awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q37960123-3D8125C5-212F-4D47-9CA3-189462C283F0
Q37960123-3D8125C5-212F-4D47-9CA3-189462C283F0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37960123-3D8125C5-212F-4D47-9CA3-189462C283F0
Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus.
P2860
Q37960123-3D8125C5-212F-4D47-9CA3-189462C283F0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37960123-3D8125C5-212F-4D47-9CA3-189462C283F0
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f55bc3ef9d5c87422a568efa34c4c8ca0112ab6d
P2860
Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.